The bear case for EVGN (such as it is) is that having collaborations will all of the leading ag-biotech companies (MON, DD, SYT) makes it hard to envision a buyout.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”